Yahoo · Sep 30, 2026
VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD).
VN
NASDAQ · VNDA
Vanda Pharmaceuticals Inc.
Healthcare · Biotechnology
$4.52
Up+$0.04 (+0.88%)
Updated Oct 8, 2026, 1:54 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 390.01M
- P/E ratio
- -4.61
- Dividend yield
- 0.00%
- 52-week range
- $4.27 – $9.94
- Volume
- 1.8M
- Avg. volume
- 761.61K
Price performance · VNDA
VNDA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
VNDA closed at $4.52 after 20 trading sessions, down 13.90% for the selected period.
- Last close
- $4.52
- Period change
- -13.90%
- Period low
- $4.52
- Period high
- $5.25
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $4.60 | $4.60 | $4.43 | $4.52 | 1.8M |
| Oct 5, 2026 | $4.59 | $4.60 | $4.49 | $4.58 | 726.8K |
| Oct 2, 2026 | $4.85 | $4.85 | $4.565 | $4.63 | 1.45M |
| Oct 1, 2026 | $4.90 | $4.955 | $4.79 | $4.81 | 1.35M |
| Sep 30, 2026 | $5.16 | $5.19 | $4.90 | $4.91 | 3.08M |
| Sep 29, 2026 | $5.17 | $5.18 | $5.00 | $5.03 | 2.67M |
| Sep 28, 2026 | $5.05 | $5.17 | $4.965 | $5.17 | 813.08K |
| Sep 25, 2026 | $5.01 | $5.07 | $4.93 | $5.05 | 722.7K |
| Sep 24, 2026 | $5.05 | $5.06 | $4.94 | $4.98 | 921.14K |
| Sep 23, 2026 | $5.32 | $5.33 | $4.995 | $5.04 | 904.77K |
| Sep 22, 2026 | $5.19 | $5.23 | $5.10 | $5.21 | 617.87K |
| Sep 21, 2026 | $5.15 | $5.168 | $5.05 | $5.155 | 938.83K |
| Sep 18, 2026 | $5.085 | $5.15 | $5.035 | $5.13 | 1.66M |
| Sep 17, 2026 | $4.99 | $5.17 | $4.99 | $5.11 | 646.83K |
| Sep 16, 2026 | $5.00 | $5.03 | $4.94 | $5.00 | 441.25K |
| Sep 15, 2026 | $5.17 | $5.17 | $4.955 | $4.99 | 758.87K |
| Sep 14, 2026 | $5.12 | $5.19 | $5.0408 | $5.15 | 817.81K |
| Sep 11, 2026 | $5.10 | $5.17 | $5.05 | $5.09 | 701.23K |
| Sep 10, 2026 | $5.20 | $5.20 | $5.01 | $5.04 | 958.22K |
| Sep 9, 2026 | $5.29 | $5.3463 | $5.215 | $5.25 | 715.01K |
Latest VNDA news
The latest Smart Investors Daily articles mentioning VNDA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VNDA research
Overview
Company profile and research snapshot.
Company profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $11.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Aug 10, 2026 | B. Riley Securities | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 30, 2026
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.
Yahoo · Sep 29, 2026
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends to discuss these data with the U.S. Food and Drug Administration (FDA) and to submit a supplemental New Drug Application (sNDA) seeking approval of HETLIOZ® for DSWPD. If approved, HETLIOZ® would be the first FDA-approved medicine indicated for this condition.
Benzinga · Sep 23, 2026
Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
